Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone Group of Urological Radiotherapy (GFRU)
Illustration of the concerns when managing a patient with BCR, and the main relevant trials addressing these issues. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 15, 2023 Category: Cancer & Oncology Authors: Loic Ah-Thiane, Paul Sargos, Olivier Chapet, Marjory Jolicoeur, Mario Terlizzi, Carl Salembier, Jihane Boustani, C élia Prevost, Sonya Gaudioz, Talar Derashodian, Samuel Palumbo, Olivier De Hertogh, Gilles Créhange, Thomas Zilli, Stéphane Supiot Tags: Tumour Review Source Type: research
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma
Cholangiocarcinomas (CCAs) are subdivided into intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA) (further divided into perihilar (pCCA) and distal (dCCA)) based on their location. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 15, 2023 Category: Cancer & Oncology Authors: Angela Lamarca, Lorena Ostios, Mair éad G McNamara, Carlos Garzon, Jack P Gleeson, Julien Edeline, Ana Herrero, Richard A Hubner, Victor Moreno, Juan W Valle Tags: Anti-tumour Treatment Source Type: research
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: can we inform future trial design?
High-grade osteosarcoma is an aggressive bone sarcoma with a peak incidence in adolescence [1], with one-third of the patients experiencing disease progression/recurrence during or after first-line treatment consisting of multidrug chemotherapy and surgery of the primary tumor and metastatic lesions [2 –5]. At progression or recurrence, the 5-year overall survival (OS) is dismal, below 30%, with an extremely poor prognosis, unless a second complete surgical remission is achieved [2,3]. Despite many trials being performed, there is no established standard therapy besides surgery for recurrent/ref ractory osteosarcoma, nor...
Source: Cancer Treatment Reviews - September 15, 2023 Category: Cancer & Oncology Authors: Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, Marie-C écile le Deley, Natasha van Eijkelenburg, Pascaline Boudou-Rouquette, Severine Risbourg, Sandra J. Strauss, Emanuela Palmerini, Kjetil Boye, Leo Kager, Stefanie Hecker-Nolting, Antonin Marchais, Tags: Systematic or Meta-analysis Studies Source Type: research
Efficacy and Safety of PARP inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Clinical Trials
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths among men in the United States, with an estimated 288,300 new cases and 34,700 deaths in 2023 [1]. Over the last decade, the landscape of treatments has changed significantly with the approval of several agents that improve overall survival in patients with metastatic prostate cancer, including androgen-receptor signaling inhibitors (ARSI) (abiraterone acetate [2], enzalutamide [3], apalutamide [4], and darolutamide [5]), and radioligand therapies (radium-223 [6] and 177Lu-PSMA-617 [7]). (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 8, 2023 Category: Cancer & Oncology Authors: Giovanni Maria Iannantuono, Elias Chandran, Charalampos S. Floudas, Hyoyoung Choo-Wosoba, Gisela Butera, Mario Roselli, James L. Gulley, Fatima Karzai Tags: Anti-tumour Treatment Source Type: research
Patient-Reported Outcome Measure to Implement Routine Assessment of Cancer Survivors ’ Unmet Needs: An Overview of Reviews and COSMIN Analysis
The number of cancer survivors (CSs) worldwide is increasing as a consequence of improved screening and early detection, advances in treatment and technology, enhanced follow-up care, and world population aging.[1 –4] Individuals are considered ‘cancer survivor’ from the moment of their diagnosis on, for the rest of their life.[5] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 8, 2023 Category: Cancer & Oncology Authors: Angela Contri, Sara Paltrinieri, Martina Torreggiani, Maria Chiara Bassi, Elisa Mazzini, Monica Guberti, Isabella Campanini, Luca Ghirotto, Stefania Fugazzaro, Stefania Costi Tags: General and Supportive Care Source Type: research
Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome
With more than 2 million new diagnoses per year, breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death worldwide [1]. Most BC cases are diagnosed at an early stage, with the disease limited to the mammary gland and the loco-regional lymph nodes. Hormone receptor positive (HR-positive) BC is the most frequent molecular subtype, accounting for about 70% of the diagnoses [2].Fig 1.Table 1. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 7, 2023 Category: Cancer & Oncology Authors: Linda Cucciniello, Giovanna Garufi, Rossana Di Rienzo, Claudia Martinelli, Giuliana Pavone, Mario Giuliano, Grazia Arpino, Filippo Montemurro, Lucia Del Mastro, Michelino De Laurentiis, Fabio Puglisi Tags: Anti-tumour Treatment Source Type: research
Local control strategies for management of NSCLC with oligoprogressive disease
At diagnosis, up to 50% of patients with non-small cell lung cancer (NSCLC) present with advanced stage [1]. Metastatic NSCLC is an heterogeneous disease and its prognosis depends on predictive biomarkers such as PD-L1 status and the presence of genomic alterations, as well as prognostic markers based on the tumor burden defined by the number of metastatic lesions [2 –4]. In the recent decade, the introduction of immune checkpoint blockers (ICB) and targeted therapies for oncogene-addicted NSCLC have shifted the treatment paradigm and prognosis of patients with advanced NSCLC. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 1, 2023 Category: Cancer & Oncology Authors: Antoine Mavrikios, Jordi Remon, Cl ément Quevrin, Olaf Mercier, Lambros Tselikas, Angela Botticella, Eliot Nicolas, Eric Deutsch, Benjamin Besse, David Planchard, Fabrice Barlesi, Cécile Le Péchoux, Antonin Levy Tags: Anti-tumour Treatment Source Type: research
The role of radiation therapy in the management of primary retroperitoneal sarcoma: a systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association
Retroperitoneal sarcomas (RPS) are rare malignancies that can be difficult to manage given their large and often irregular size, and tendency to involve critical retroperitoneal structures. While surgery is the cornerstone of treatment, the role of radiation therapy (RT) remains controversial, with differences in practice between centres. Some centres recommend preoperative RT if macroscopically complete resection is thought not to be feasible based on preoperative imaging. Other centres do not generally recommend RT, or recommend RT for specific sub-types such as low grade liposarcoma. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 28, 2023 Category: Cancer & Oncology Authors: Anna Lawless, Deborah Di-Xin Zhou, Joshua McDonough, Helen Lo, Jasmine Mar, Smaro Lazarakis, Iain Ward, Joanna Connor, Stephen R Thompson, David Coker, Andrew Johnston, David E Gyorki, Angela M Hong Tags: Systematic or Meta-analysis Studies Source Type: research
From Genetics to Therapy: Unraveling the Complexities of Richter Transformation in Chronic Lymphocytic Leukemia
With an estimated incidence of 4.7 new cases per 100,000 individuals, chronic lymphocytic leukemia (CLL) is the most common form of chronic leukemia in the USA and in Europe. [1] In 1928, Dr. Maurice N. Richter described a clinical case of a male diagnosed with CLL who developed constitutional symptoms. The enlarged lymph nodes found in the necropsy were diagnosed with a reticular cell sarcoma. [2] Since then, the occurrence of an aggressive lymphoma in patients with a previous or concurrent diagnosis of CLL has been termed Richter transformation (RT), a nosological entity recognized in the World Health Organization (WHO) ...
Source: Cancer Treatment Reviews - August 24, 2023 Category: Cancer & Oncology Authors: Pau Abrisqueta, Ferran Nadeu, Jan Bosch-Schips, Gloria Iacoboni, Angel Serna, Alba Cabirta, Lucrecia Y áñez, Leticia Quintanilla-Martínez, Francesc Bosch Tags: Anti-tumour Treatment Source Type: research
Tucatinib's Journey from Clinical Development to Clinical Practice: New Horizons for HER2-Positive Metastatic Disease and Promising Prospects for Brain Metastatic Spread
Metastatic breast cancer (BC) is the second most common cancer after lung cancer, associated with the development of brain metastases (BMs) [1]. As cancer research breakthroughs considerably improved survival of patients with advanced BC in the last decades, the incidence of BMs has also increased accordingly (Figure 1) [2]. Hence, new treatment options and therapeutic strategies are needed to ensure a survival advantage for patients with BMs. However, data about the efficacy of anti-cancer agents on BMs are limited. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 22, 2023 Category: Cancer & Oncology Authors: Carmen Criscitiello, Chiara Corti, Michelino De Laurentiis, Giampaolo Bianchini, Barbara Pistilli, Saverio Cinieri, Lucio Castellan, Grazia Arpino, Pierfranco Conte, Francesco Di Meco, Alessandra Gennari, Valentina Guarneri, Luca Visani, Lorenzo Livi, Pao Tags: Anti-tumour Treatment Source Type: research
Multimodality treatment of primary cardiac angiosarcoma: A systematic literature review
Primary cardiac neoplasms are rare entities with an incidence of 1.38 per 100,000 and occur more than 30 times less frequent than metastatic disease of the heart [1,2]. In adults, approximately one fourth of the primary cardiac tumors are malignant, with 75% – 95% of them being sarcomas [3–5]. Angiosarcoma has been recognized as a common primary cardiac sarcoma (PCS) histology arising preferentially in the right atrium between the third and the fifth decade of life [2–8]. The fact that angiosarcomas tend to be bulky, infiltrate the cardiac muscle, and metastasize early (especially to the lungs) in conjunction with no...
Source: Cancer Treatment Reviews - August 15, 2023 Category: Cancer & Oncology Authors: Anastasia Stergioula, Stefania Kokkali, Evaggelos Pantelis Tags: Systematic or Meta-analysis Studies Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 12, 2023 Category: Cancer & Oncology Source Type: research
Novel targets for immune-checkpoint inhibition in cancer
Over the last decade, immune-checkpoint inhibitors (ICI) have revolutionized cancer care, offering patients an alternative to chemotherapy or targeted therapies and a chance at long-term remission across many tumor types. The first two immune-checkpoint receptors for which clinically efficient inhibitors were successfully developed were the cytotoxic lymphocyte antigen-4 (CTLA-4) and the programmed death-1 (PD-1) receptor. Most solid tumors and a subset of hematologic malignancies benefit from using one or both drug classes. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 12, 2023 Category: Cancer & Oncology Authors: Maxime Borgeaud, Jose Sandoval, Michel Obeid, Giuseppe Banna, Olivier Michielin, Alfredo Addeo, Alex Friedlaender Tags: Anti-tumour Treatment Source Type: research
Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy
Small-cell lung cancer (SCLC) is an extremely malignant and aggressive neuroendocrine tumor that accounts for ∼ 15% of all lung cancers[1]. Despite advances in diagnostic techniques and treatment strategies, the five-year survival rate for patients with SCLC remains ∼ 7%[2]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 7, 2023 Category: Cancer & Oncology Authors: Yunfei Chen, Hui Li, Yun Fan Tags: Anti-tumour Treatment Source Type: research
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Lung cancer is the leading cause of cancer incidence and mortality, with an estimated 2 million diagnosed cases and 1.8 million deaths per year reported worldwide [1]. In 2022, an estimated 0.87 million new cases and 0.76 million deaths of lung cancer were reported in China [2]. Non –small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85 % of all cases [3–5]. Over the past decade, advances in our understanding of cell signaling pathways that control cell survival have identified genetic and epigenetic alterations, which promote cell prolif eration and tumorigenesis. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - August 6, 2023 Category: Cancer & Oncology Authors: Qianming Bai, Jialei Wang, Xiaoyan Zhou Tags: Anti-tumour Treatment Source Type: research
